Skip to main
  1. Stocks
  2. Annexon, Inc
  3. Forecast
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Annexon is attractive fundamentally because its differentiated, first-in-class C1q platform targets the earliest step in the classical complement pathway, creating multiple shots on goal across high-unmet-need markets in neurology, ophthalmology, and autoimmune disease. The near-term GBS catalyst looks particularly compelling: tanruprubart showed rapid functional improvement in Phase 3, FORWARD’s first 10 patients improved within days, and the company expects a BLA submission in 4Q26, while the market is concentrated at roughly 8,000 U.S. cases and around 50 key centers. In GA, ARCHER II’s 659-patient design, over-enrollment, high compliance, and enrichment strategy support a meaningful readout in 4Q26, and even using conservative assumptions the stock appears to reflect limited value for vonaprument despite its potential to add substantial long-term sales.

Bears say

Annexon is viewed negatively because its lead asset vonaprument already failed Phase 2 on the primary GA lesion-growth endpoint, and the remaining vision-preservation signal looks fragile, driven by a small subset of patients while BCVA measurement noise adds uncertainty. In Phase 3, the company is relying on a difficult setup to reach statistical significance, requiring a low response rate against an enriched sham population, while competing GA drugs from larger, better-resourced players already have commercial momentum. Financially, Annexon finished 1Q26 with $225M in cash, but it is expected to keep incurring net losses and may need additional capital before key readouts in 4Q26 and 3Q27, creating dilution risk if development disappoints.

Annexon, Inc (ANNX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Annexon, Inc (ANNX) Analyst Forecast & Price Prediction

Get the latest Annexon, Inc (ANNX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Annexon, Inc (ANNX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 7 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Annexon, Inc (ANNX) Analyst Forecast & Price Prediction

Get the latest Annexon, Inc (ANNX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Annexon, Inc (ANNX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANNX stock data and trends